Comparative Efficacy of Intramuscular Oxytocin and Carboprost Tromethamine in Postpartum Hemorrhage Prophylaxis: A Randomized Controlled Trial
DOI:
https://doi.org/10.55489/ijmr.1201202453Keywords:
Postpartum hemorrhage, Oxytocin, Carboprost tromethamine, Third stage of labor, Uterotonics, Blood lossAbstract
Background: Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality worldwide, despite the preventive benefits of active management in the third stage of labor. Oxytocin is widely used for PPH prevention; however, its effectiveness is sometimes limited, necessitating alternative or additional uterotonics. Carboprost tromethamine, a prostaglandin analogue, offers potential advantages, but comparative studies are limited. This study aimed to compare the efficacy of intramuscular oxytocin (10 units) versus intramuscular carboprost tromethamine (125 µg) in reducing blood loss during the third stage of labor and in minimizing the need for additional uterotonics.
Methods: In a randomized controlled trial, 266 women undergoing vaginal delivery were assigned to receive either oxytocin (Group A) or carboprost tromethamine (Group B) as PPH prophylaxis. Primary outcomes included the duration of the third stage of labor and estimated blood loss, with secondary outcomes of additional uterotonic requirement, hemoglobin change, and side effects.
Results: Mean third-stage duration was significantly shorter in the carboprost group (6.18 min) than the oxytocin group (6.71 min, p < 0.05). Mean blood loss was also significantly lower with carboprost (183.44 ml) compared to oxytocin (285.77 ml, p < 0.001). Additional uterotonics were needed less frequently in the carboprost group (3%) versus the oxytocin group (15.8%, p < 0.05). Diarrhea was more common in the carboprost group.
Conclusion: Carboprost tromethamine demonstrated superior efficacy in reducing blood loss and third-stage duration compared to oxytocin, with a manageable side effect profile. These findings support carboprost as an effective alternative for PPH prophylaxis.
References
1. Mukherje J, Ganguly RP, Saha SK Maternal mortality due to hemorrhage with emphasis on post-partum haemorrhage. J ObstetGynecol India.2001;51(5):130- 33
2. Christopher B. Lynch, Moore Keith. A textbook of postpartum hemorrhage, a comprehensive guide to evaluate management and surgical intervention. FOGSI publication 2006; 8.
3. Park K. Preventive medicine in obstetrics, pediatrics and geriatrics, chapter 9 in textbook of preventive and social medicine, 22ndedition. Jabalpur, M/S Banarri Das Bharot, 2013; 516-519.
4. Moir JC 1955. The history of present-day use of ergot. Can med ASS J.72: 727-34.
5. Seow KM, Chen KH, Wang PH, Lin YH, Hwang JL. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in infertile women with twin pregnancy undergoing elective cesarean delivery. Taiwan J Obstet Gynecol. 2017;56(3):273-5. DOI: https://doi.org/10.1016/j.tjog.2017.04.001 PMid:28600032
6. Kemenkes RI [Ministry of Health, Republic of Indonesia]. Pusat Data dan Informasi [Center of Data and Information]. 2014.
7. Leduc D, Senikas V, Lalonde AB, Ballerman C, Biringer A, Delaney M, et al. Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage. J ObstetGynaecol Canada. 2009;31(10):980-93. DOI: https://doi.org/10.1016/S1701-2163(16)34329-8 PMid:19941729
8. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva, Switzerland: WHO Press; 2012. Available at: http://apps.who.int/iris/bitstream/10665/75411/1/978 9241548502_eng.pdf
9. Gizzo S, Patrelli TS, Gangi S Di, Carrozzini M, Saccardi C, Zambon A, et al. Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: A systematic review. Reprod Sci. 2013;20(9):1011-9. DOI: https://doi.org/10.1177/1933719112468951 PMid:23296037
10. Alwani M, Singh S, Thakur R, Mishra S. A randomized study comparing rectally administered misoprostol after spinal anesthesia versus intramuscular oxytocin for prevention of postpartum hemorrhage in caesarean section. Int J Reprod Contraception, Obstet Gynecol. 2014;33(3):512-5. DOI: https://doi.org/10.5455/2320-1770.ijrcog20140909
11. ElbohotyAEH, Mohammed WE, Sweed M, BahaaEldin AM, Nabhan A, Abd-El-Maeboud KHI. Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. Int J Gynecol Obstet. 2016;134(3):324-8. DOI: https://doi.org/10.1016/j.ijgo.2016.01.025 PMid:27350226
12. Samimi M, Imani-Harsini A, Abedzadeh-Kalahroudi M. Carbetocin vs. syntometrine in prevention of postpartum hemorrhage: a double blind randomized control trial. Iran Red Crescent Med J. 2013;15(9):817-22. DOI: https://doi.org/10.5812/ircmj.7881 PMid:24616793 PMCid:PMC3929818
13. Roach MK, Abramovici A and Tita AT: Dose and duration of oxytocin to prevent postpartum hemorrhage: a review. Am J Perinatol: Dec 3, 2012 (Epub ahead of print). DOI: https://doi.org/10.1055/s-0032-1329184 PMid:23208766
14. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J ObstetGynecolReprod Biol. 2009;147(1):15-20. DOI: https://doi.org/10.1016/j.ejogrb.2009.06.018 PMid:19616358
15. Gibbins KJ, Albright CM and Rouse DJ: Postpartum hemorrhage in the developed world: whither misoprostol? Am J ObstetGynecol 208: 181-183, 2013. DOI: https://doi.org/10.1016/j.ajog.2012.07.034 PMid:22901709
16. WHO department of making pregnancy safer 2009. WHO recommendations for treatment of PPH and retained placenta. WHO: Geneva. 2013. available from www.who.int.
17. Chelmow D. Postpartum hemorrhage prevention: clinical evidence. BMJ 2011; 1- 6.
18. Hofmeyr GJ, Gulmezoglu AM. New development in the management of postpartum hemorrhage. In: Bonner J, editor. Recent advances in obstetrics and gynaecology. 21st ed. London: Churchill Livingstone; 2000. p. 56-66.
19. Ambika S. Patil, Vibhavaree Dadavate and Vidya A. Thobbi. Carboprost versus oxytocin for active management of third stage of labour. Al Am een J Med Sci 2016; 9(3):196-201
20. Lamba A et al. Int J Reprod Contracept Obstet Gynecol. 2016; 5(7):2151-2154. DOI: https://doi.org/10.18203/2320-1770.ijrcog20162082
21. Bai J, Sun Q, Zhai H, et al. A comparison of oxytocin and carboprost in prevention of PPH in high risk patients in caesarean section. Exp Ther Med. 2014;7:46-50. DOI: https://doi.org/10.3892/etm.2013.1379 PMid:24348762 PMCid:PMC3861477
22. Management of the third stage of labour to prevent postpartum haemorrhage (joint statement). The Hague and London: International Confederation of Midwives and International Federation of Gynaecology and Obstetrics, 2003.
23. Buttino L Jr, Garite TJ. The use of 15 methyl F2 alpha prostaglandin (Prostin 15 M) for the control of postpartum hemorrhage. Am J Perinatol. 1986; 3:241-243. DOI: https://doi.org/10.1055/s-2007-999875 PMid:3487334
24. Managing complications of pregnancy and childbirth: A guide for midwives and doctors. Geneva: World Health Organization, United Nations Population Fund, United Nations Children's Fund and The World Bank, 2003. (WHO/ RHR/00.7).
25. Patil AS, Dadavate V, Thobbi VA. Carboprost versus oxytocin for active management of third stage of labour. Al Am een J Med Sci 2016; 9(3):196-201
26. Madhulika, Sushma Singh, Smita Rai. Comparison of carboprost with oxytocin in third stage of labour. Int J Clin Obstet Gynaecol 2019;3(5):318-321. DOI: https://doi.org/10.33545/gynae.2019.v3.i5e.371
27. Sunil Kumar KS, Shyam S, Batakurki P. Carboprost Versus Oxytocin for Active Management of Third Stage of Labor: A Prospective Randomized Control Study. J ObstetGynaecol India. 2016;66(Suppl 1):229-234. DOI: https://doi.org/10.1007/s13224-016-0842-x PMid:27651609 PMCid:PMC5016447
28. Abdel-Aleem H, Abol Oyoun EM, Moustafa SA, et al. Carboprost trometamol in the management of the third stage of labor. Int J Gynaecol Obstet. 1993;42:247-50. DOI: https://doi.org/10.1016/0020-7292(93)90219-M PMid:7901080
29. Lamont RF, Morgan DJ, Logue M, Gordon H. A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage. Prostaglandins Other Lipid Mediat. 2001; 66:203-210. DOI: https://doi.org/10.1016/S0090-6980(01)00154-X PMid:11577783
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.
